Boston Scientific (NYSE: BSX) director Yoshiaki Fujimori to step down at 2026 meeting

Rhea-AI Filing Summary

Boston Scientific Corporation disclosed that director Yoshiaki Fujimori has informed the company he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.

Mr. Fujimori will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision is not due to any disagreement with the company. The Board and its Nominating and Governance Committee will continue reviewing Board size and composition and may consider adding directors after his departure.

0000885725false00008857252026-02-022026-02-020000885725us-gaap:CommonStockMember2026-02-022026-02-020000885725bsx:SeniorNotedue2027Member2026-02-022026-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

_____________________________________________________________________

Date of Report (Date of earliest event reported): February 2, 2026

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-11083

04-2695240

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                 01752-1234

    (Address of principal executive offices)                           (Zip Code)

(508) 683-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value per share

BSX

New York Stock Exchange

0.625% Senior Notes due 2027

BSX27

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Compensatory Arrangements of Certain Officers.

On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Mr. Fujimori has served as a member of the Board of Directors (the “Board”) of the Company since July 2016 and currently serves as the chair of the Risk, Science and Technology Committee. Mr. Fujimori will continue to serve as a director and in his committee roles until the 2026 Annual Meeting. Mr. Fujimori’s decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.

The Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board following Mr. Fujimori’s departure is in the best interest of the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:			February 5, 2026			BOSTON SCIENTIFIC CORPORATION
						By:			/s/ Susan Thompson
									Susan Thompson
									Vice President, Chief Corporate Counsel and Assistant Secretary

FAQ

What board change did Boston Scientific (BSX) announce in this 8-K?

Boston Scientific announced that director Yoshiaki Fujimori will not stand for re-election at the 2026 Annual Meeting. He will continue serving on the Board and in his committee roles until that meeting, after which his board service will conclude.

When will Yoshiaki Fujimori leave the Boston Scientific (BSX) board?

Yoshiaki Fujimori will leave the Boston Scientific Board at the company’s 2026 Annual Meeting of Stockholders. Until that meeting, he remains a director and continues to serve as chair of the Risk, Science and Technology Committee.

Why is Yoshiaki Fujimori not standing for re-election at Boston Scientific (BSX)?

The company states that Mr. Fujimori’s decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with Boston Scientific. No additional reasons are provided in the disclosure beyond his decision to step down.

What roles does Yoshiaki Fujimori hold at Boston Scientific (BSX) before his departure?

Before his planned departure at the 2026 Annual Meeting, Yoshiaki Fujimori serves as a member of Boston Scientific’s Board of Directors and as chair of the Board’s Risk, Science and Technology Committee, positions he has held following his initial appointment in July 2016.

How long has Yoshiaki Fujimori served on the Boston Scientific (BSX) board?

Yoshiaki Fujimori has served on Boston Scientific’s Board of Directors since July 2016. His service will extend through the company’s 2026 Annual Meeting of Stockholders, giving him roughly a decade of board tenure before stepping down.

Will Boston Scientific (BSX) replace Yoshiaki Fujimori on its board?

Boston Scientific states that its Board and Nominating and Governance Committee regularly review board size and composition and will continue evaluating whether adding directors after Mr. Fujimori’s departure is in the company’s best interest, but no specific replacement decision is disclosed.